| Title |
Impact of the AT2 Receptor Agonist C21 on Blood Pressure and Beyond
|
|---|---|
| Published in |
Current Hypertension Reports, July 2012
|
| DOI | 10.1007/s11906-012-0291-6 |
| Pubmed ID | |
| Authors |
Sébastien Foulquier, U. Muscha Steckelings, Thomas Unger |
| Abstract |
It is now widely accepted that the angiotensin AT(2) receptor (AT(2)R) plays an important protective role during pathophysiologic conditions, acting as a repair system. The development of the first selective nonpeptide AT(2)R agonist C21 accelerated our understanding of AT(2)R-mediated protective signaling and actions. This article reviews the impact of C21 on blood pressure in normotensive and hypertensive animal models. Although C21 does not act as a classical antihypertensive drug, it could be useful in preventing hypertension-induced vascular and other end organ damages via anti-apoptotic, anti-fibrotic and anti-inflammatory actions. In particular, a strong body of evidence started to emerge around its anti-inflammatory feature. This property should be further investigated for potential clinical indications in cardiovascular diseases and beyond. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Researcher | 5 | 18% |
| Student > Ph. D. Student | 5 | 18% |
| Student > Master | 4 | 14% |
| Professor | 2 | 7% |
| Other | 3 | 11% |
| Unknown | 3 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Engineering | 3 | 11% |
| Agricultural and Biological Sciences | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2017.
All research outputs
#2,618,437
of 22,721,584 outputs
Outputs from Current Hypertension Reports
#85
of 732 outputs
Outputs of similar age
#17,796
of 164,706 outputs
Outputs of similar age from Current Hypertension Reports
#2
of 4 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 732 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,706 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.